Data-Driven Timing of Optimal Lvef Assessment in Breast Cancer Patients Exposed to Trastuzumab
Jeffrey Sulpher(BC Cancer Agency), Susan Dent(Government of the United States of America), Christopher Johnson(Ottawa Hospital), Nadine Graham(University of Ottawa), Peter Andrew, H. Majeed
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589